Novo Nordisk A/S (NYSE:NVO) Receives Average Rating of “Moderate Buy” from Analysts

Novo Nordisk A/S (NYSE:NVO) has earned a consensus recommendation of “Moderate Buy” from the eight analysts that are covering the stock, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $145.67.

A number of equities analysts recently commented on NVO shares. The Goldman Sachs Group assumed coverage on shares of Novo Nordisk A/S in a research note on Thursday, May 30th. They issued a “buy” rating and a $156.00 price objective for the company. Argus raised their target price on Novo Nordisk A/S from $125.00 to $160.00 and gave the stock a “buy” rating in a research report on Monday, June 10th. BMO Capital Markets reissued an “outperform” rating and set a $163.00 price target on shares of Novo Nordisk A/S in a research report on Tuesday, June 25th. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $160.00 price objective on shares of Novo Nordisk A/S in a research report on Monday, July 1st.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of NVO. Creative Financial Designs Inc. ADV increased its holdings in Novo Nordisk A/S by 81.9% in the fourth quarter. Creative Financial Designs Inc. ADV now owns 7,954 shares of the company’s stock worth $823,000 after buying an additional 3,582 shares during the last quarter. BKM Wealth Management LLC bought a new position in shares of Novo Nordisk A/S during the 4th quarter valued at $63,000. Bruce G. Allen Investments LLC bought a new position in shares of Novo Nordisk A/S during the 4th quarter valued at $36,000. JGP Wealth Management LLC acquired a new stake in shares of Novo Nordisk A/S in the 4th quarter valued at $203,000. Finally, Dynamic Advisor Solutions LLC increased its position in Novo Nordisk A/S by 1.0% during the fourth quarter. Dynamic Advisor Solutions LLC now owns 29,619 shares of the company’s stock worth $3,139,000 after buying an additional 296 shares during the last quarter. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Stock Performance

Shares of NYSE NVO opened at $131.54 on Wednesday. Novo Nordisk A/S has a 52-week low of $77.96 and a 52-week high of $148.15. The stock has a market capitalization of $590.29 billion, a price-to-earnings ratio of 45.36, a PEG ratio of 1.32 and a beta of 0.41. The company has a quick ratio of 0.50, a current ratio of 0.70 and a debt-to-equity ratio of 0.17. The stock’s fifty day simple moving average is $138.93 and its 200 day simple moving average is $127.72.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings results on Thursday, May 2nd. The company reported $0.83 earnings per share for the quarter, topping analysts’ consensus estimates of $0.77 by $0.06. Novo Nordisk A/S had a return on equity of 91.70% and a net margin of 36.56%. The firm had revenue of $9.52 billion for the quarter, compared to analysts’ expectations of $9.23 billion. As a group, sell-side analysts forecast that Novo Nordisk A/S will post 3.38 earnings per share for the current fiscal year.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.